A couple of points to make, riffing off the tweet below, on the subject of sell-side analysts remaining bullish on Alzheimer’s disease drugs like Biogen’s (BIIB) aducanumab even when the historical failure rate is pretty much 100 percent.

Sell-side analysts are smart people who work in a dumb system called Wall Street that basically rewards them for being optimistic, even when the facts — or for biotech analysts, the clinical data — suggest otherwise.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • “If the drug fails, the stock could fall to $250, which is roughly the price at which many analysts set “zero pipeline value” for the company.”
    — why would shares in a company with nothing of value in the pipeline be priced at $250/share???

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy